Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

21 trials with published results (25%)

Research Maturity

79 completed trials (93% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

3.5%

3 terminated out of 85 trials

Success Rate

96.3%

+9.8% vs benchmark

Late-Stage Pipeline

44%

37 trials in Phase 3/4

Results Transparency

27%

21 of 79 completed with results

Key Signals

21 with results96% success

Data Visualizations

Phase Distribution

78Total
Not Applicable (5)
Early P 1 (2)
P 1 (12)
P 2 (22)
P 3 (28)
P 4 (9)

Trial Status

Completed79
Terminated3
Unknown1
Withdrawn1
Active Not Recruiting1

Trial Success Rate

96.3%

Benchmark: 86.5%

Based on 79 completed trials

Clinical Trials (85)

Showing 20 of 20 trials
NCT04687059Phase 2CompletedPrimary

An Exploratory Study of PQ Grass 27600 SU

NCT07155499Phase 1Active Not RecruitingPrimary

A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.

NCT05297760Phase 1CompletedPrimary

Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract

NCT05960266Early Phase 1Completed

Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study

NCT03101267Phase 2CompletedPrimary

A Dose-finding Study of ASP4070

NCT00070707Phase 4CompletedPrimary

Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)

NCT00127647Phase 3CompletedPrimary

An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327)

NCT00092885Phase 3CompletedPrimary

An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)

NCT00319995Phase 3CompletedPrimary

Effects of Loratadine/Montelukast vs Pseudoephedrine and Placebo in Patients With Seasonal Allergic Rhinitis (Study P04095) (COMPLETED)

NCT00406783Phase 3CompletedPrimary

Study for the Treatment of Intermittent Allergic Rhinitis With Desloratadine (Study P04683)

NCT00135629Phase 3CompletedPrimary

Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever

NCT04622917Phase 4CompletedPrimary

Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.

NCT00135642Phase 3CompletedPrimary

Grass Pollen Immunotherapy Using a Cluster Regime for Seasonal Rhinitis and Asthma

NCT02975479Phase 2CompletedPrimary

Intralymphatic Immunotherapy in Increasing Doses, Substudy

NCT00805584Phase 4CompletedPrimary

Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)

NCT00805324Phase 3CompletedPrimary

Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)

NCT03861559Phase 3CompletedPrimary

Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)

NCT03882047Phase 3CompletedPrimary

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

NCT00276016Phase 3CompletedPrimary

The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)

NCT03879772Phase 3CompletedPrimary

Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)

Scroll to load more

Research Network

Activity Timeline